(VLA) Valneva SE - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: PA (France) | Market Cap: 469m EUR | Total Return: -12.6% in 12m
Avg Turnover: 2.23M
Qual. Beats: -3
Rev. Trend: -42.3%
Qual. Beats: -1
Warnings
Interest Coverage Ratio -2.6 is critical
Altman Z'' -8.17 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Valneva SE is a French biotechnology firm specialized in the development and commercialization of vaccines for infectious diseases with significant unmet medical needs. The company maintains a portfolio of approved products, including vaccines for Japanese encephalitis (IXIARO), cholera (DUKORAL), and the first FDA-approved single-dose vaccine for chikungunya (IXCHIQ). Its clinical pipeline focuses on high-burden pathogens such as Lyme disease, Zika virus, and Shigellosis.
The specialty vaccine sector is characterized by high barriers to entry due to complex manufacturing requirements and rigorous regulatory approval processes. Valneva utilizes a business model that integrates internal R&D with strategic partnerships, often collaborating with larger pharmaceutical entities to fund late-stage clinical trials and scale global distribution. This approach helps mitigate the high capital intensity typical of the biotech industry.
Investors can further evaluate these clinical milestones and market trends by reviewing the data on ValueRay. Founded in 1998 and headquartered in Saint-Herblain, Valneva operates across major international markets including North America and Europe.
- IXCHIQ commercial rollout and market penetration drive long-term revenue growth trajectory
- Lyme disease vaccine candidate VLA15 Phase 3 clinical trial results impact valuation
- Travel vaccine demand recovery for IXIARO and DUKORAL influences quarterly earnings
- Research and development expenditures for Zika and Shigella candidates strain cash reserves
- Strategic partnerships and government funding agreements determine future capital allocation needs
| Net Income: -138.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -4.52 > 1.0 |
| NWC/Revenue: 68.59% < 20% (prev 97.20%; Δ -28.61% < -1%) |
| CFO/TA -0.18 > 3% & CFO -65.9m > Net Income -138.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.1m) vs 12m ago 11.84% < -2% |
| Gross Margin: 29.46% > 18% (prev 0.47%; Δ 2.90k% > 0.5%) |
| Asset Turnover: 36.60% > 50% (prev 38.58%; Δ -1.98% > 0%) |
| Interest Coverage Ratio: -2.62 > 6 (EBITDA TTM -85.8m / Interest Expense TTM 41.0m) |
| A: 0.29 (Total Current Assets 201.4m - Total Current Liabilities 94.2m) / Total Assets 372.0m |
| B: -1.91 (Retained Earnings -711.2m / Total Assets 372.0m) |
| C: -0.25 (EBIT TTM -107.6m / Avg Total Assets 427.1m) |
| D: -2.03 (Book Value of Equity -600.1m / Total Liabilities 295.3m) |
| Altman-Z'' = -8.17 = D |
| DSRI: 0.36 (Receivables 10.1m/33.5m, Revenue 156.3m/186.1m) |
| GMI: 1.58 (GM 29.46% / 46.56%) |
| AQI: 1.17 (AQ_t 0.10 / AQ_t-1 0.08) |
| SGI: 0.84 (Revenue 156.3m / 186.1m) |
| TATA: -0.19 (NI -138.0m - CFO -65.9m) / TA 372.0m) |
| Beneish M = -3.24 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at EUR 2.47 with a total of 299,795 shares traded.
Over the past week, the price has changed by +0.08%,
over one month by +3.90%,
over three months by -48.97% and
over the past year by -12.61%.
Valneva SE has no consensus analysts rating.
P/E Forward = 666.6667
P/S = 3.0
P/B = 4.2871
Revenue TTM = 156.3m EUR
EBIT TTM = -107.6m EUR
EBITDA TTM = -85.8m EUR
Long Term Debt = 161.3m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 21.0m EUR (from shortTermDebt, last quarter)
Debt = 237.6m EUR (from shortLongTermDebtTotal, last quarter) + Leases 28.1m
Net Debt = 132.3m EUR (calculated: Debt 237.6m - CCE 105.3m)
Enterprise Value = 601.3m EUR (469.0m + Debt 237.6m - CCE 105.3m)
Interest Coverage Ratio = -2.62 (Ebit TTM -107.6m / Interest Expense TTM 41.0m)
EV/FCF = -8.70x (Enterprise Value 601.3m / FCF TTM -69.1m)
FCF Yield = -11.50% (FCF TTM -69.1m / Enterprise Value 601.3m)
FCF Margin = -44.23% (FCF TTM -69.1m / Revenue TTM 156.3m)
Net Margin = -88.30% (Net Income TTM -138.0m / Revenue TTM 156.3m)
Gross Margin = 29.46% ((Revenue TTM 156.3m - Cost of Revenue TTM 110.3m) / Revenue TTM)
Gross Margin QoQ = 15.29% (prev 24.36%)
Tobins Q-Ratio = 1.62 (Enterprise Value 601.3m / Total Assets 372.0m)
Interest Expense / Debt = 17.26% (Interest Expense 41.0m / Debt 237.6m)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -80.7m (EBIT -107.6m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 2.14 (Total Current Assets 201.4m / Total Current Liabilities 94.2m)
Debt / Equity = 3.10 (Debt 237.6m / totalStockholderEquity, last quarter 76.7m)
Debt / EBITDA = -1.54 (negative EBITDA) (Net Debt 132.3m / EBITDA -85.8m)
Debt / FCF = -1.91 (negative FCF - burning cash) (Net Debt 132.3m / FCF TTM -69.1m)
Total Stockholder Equity = 129.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -32.32% (Net Income -138.0m / Total Assets 372.0m)
RoE = -16.41% (Net Income TTM -138.0m / Total Stockholder Equity 841.1m)
RoCE = -10.73% (EBIT -107.6m / Capital Employed (Equity 841.1m + L.T.Debt 161.3m))
RoIC = -27.00% (negative operating profit) (NOPAT -80.7m / Invested Capital 298.8m)
WACC = 9.30% (E(469.0m)/V(706.6m) * Re(7.45%) + D(237.6m)/V(706.6m) * Rd(17.26%) * (1-Tc(0.25)))
Discount Rate = 7.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 69.22 | Cagr: 10.03%
[DCF] Fair Price = unknown (Cash Flow -69.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.28 | # QB: -3
Revenue Correlation: -42.33 | Revenue CAGR: -10.29% | SUE: -2.05 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=-11.76% | Revisions=N/A | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.08 | Chg30d=+30.43% | Revisions=N/A | Analysts=2
EPS current Year (2026-12-31): EPS=-0.38 | Chg30d=-4.69% | Revisions=+25% | GrowthEPS=+44.0% | GrowthRev=-14.8%
EPS next Year (2027-12-31): EPS=0.27 | Chg30d=N/A | Revisions=+25% | GrowthEPS=+171.7% | GrowthRev=+99.9%
[Analyst] Revisions Ratio: +25%